Amin Alirezaylavasani's research while affiliated with University of Oslo and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (6)
Background
SARS-CoV-2 vaccination in rheumatoid arthritis (RA) patients treated with B cell-depleting drugs induced limited seroconversion but robust cellular response. We aimed to document specific T and B cell immunity in response to vaccine booster doses and breakthrough infection (BTI).
Methods
We included 76 RA patients treated with rituximab...
People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role tha...
Background
Kidney transplant recipients (KTR) are at high risk for severe COVID-19 and have demonstrated poor response to vaccination, making it unclear whether successive vaccinations offer immunity and protection.
Methods
We conducted a serologically guided interventional study where KTR patients that failed to seroconvert were revaccinated and...
The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding
domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a super-spreader event have...
The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a super-spreader event have...
The new SARS-CoV-2 variant of concern (VOC) Omicron has more than 30 mutations in the receptor binding domain (RBD) of the Spike protein enabling viral escape from antibodies in vaccinated individuals and increased transmissibility. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a...
Citations
... Vaccine responder patients (>200 BAU/mL), however, had some reconstituted B cells, expressing light-chain Ig kappa and Lambda with an activated profile (CD71, HLA-DR in clusters 1 and 2) (Supplementary Figures S3A-D). Among responder patients after D2 or D3, we were able to detect the low frequency of Spike-binding B cells that either bound the receptor-binding domain (RBD) of Spike (Spike + RBD + ) or that could bind Spike but not RBD (Spike + RBD -) [ Figure 2A; the regions were as previously described (21,22)]. At 1 month after D2 (D2m1) and D3 (D3m1), 3/6 and 5/6 responder patients had both RBD + Spike + B cells and RBD -Spike + B cells ( Figure 2B). ...
... 8,9 T cell responses, in addition to long-lived B cells, are important for protection against severe disease, immune longevity, and recognising new viral variants. [10][11][12][13] In addition, T cells specific for seasonal coronaviruses cross-react with SARS-CoV-2 epitopes, possibly contributing to protective responses. 13 As many countries are facing ageing populations, longitudinal studies on the effects of ageing have been established to improve the health-care needs in older adults 14 and assess the effect of the COVID-19 pandemic. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/621472808718340-1525182072647_Q64/Asia-Sophia-Wolf.jpg)
... Various countries have implemented travel restrictions as an "emergency break" to curb virus introduction. Although the end of the epidemic in some countries seems to be on the horizon following mass vaccination, some strains of SARS-CoV-2 are feared to cause new waves of infection due to vaccine breakthrough as it has been observed in many parts of the world (Boekel et al. 2022;Johnson et al. 2022;Kared et al. 2022). ...
... Some authors report that reinfection rates with Omicron are far superior to reinfection rates with Beta and Delta [91], and that NAbs elicited by pre-Omicron VOCs or by variant-specific vaccines are less effective against Omicron [36,48,68,80,92]. Others report that breakthrough infection with pre-Omicron VOCs elicits cross-reactive antibodies with the ability to neutralize Omicron [49,93,94]. Converging reports indicate that an Omicron BA.1 breakthrough infection elicits antibodies with neutralizing activity against Omicron BA.1 and pre-Omicron VOCs [36,48,92,95,96] but poorly cross-neutralizing other Omicron sublineages [97]. ...
